RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial – JAMA Neurology

Commentary on Twitter

In poorly controlled #ParkinsonDisease, study found adding a COMT inhibitor to existing treatment is not as good as adding a MAOB inhibitor or dopamine agonist https://t.co/0GrA2YYMbI pic.twitter.com/d4VNnom2zk

— JAMA Neurology (@JAMANeuro) December 28, 2021